Research Topics
| Emmanuel S AntonarakisSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Clinical problem-solving. Beware of first impressionsOluwaseun O Falade
Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore 21224, USA
N Engl J Med 359:628-34. 2008- Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsEmmanuel S Antonarakis
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, CRB1 1M45, 1650 Orleans Street, Baltimore, MD 21231, USA
Cancer 118:1533-42. 2012..However, it is unknown whether changes in PSA kinetics influence metastasis-free survival (MFS)... - Targeting angiogenesis for the treatment of prostate cancerEmmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Prostate Cancer Research Program, 1650 Orleans Street, CRB1 1M45, Baltimore, MD 21231 1000, USA 1 443 287 0553 1 410 614 8397
Expert Opin Ther Targets 16:365-76. 2012..These barriers will hopefully be overcome with the advent of more potent agents, the use of dual angiogenesis inhibition and the design of more informative clinical trials... - Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effectsEmmanuel S Antonarakis
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
Expert Opin Investig Drugs 19:311-4. 2010..These studies provide a rationale for designing clinical trials that combine low-dose cyclophosphamide with GM-CSF-secreting cell-based immunotherapy in patients with prostate and other cancers... - Orientation of the stethoscope around the neck: a random phenomenon or an indicator of cerebral lateralisation? Cross-sectional surveyEmmanuel S Antonarakis
Department of General Medicine, University Hospital of Wales, Cardiff, UK
Laterality 11:287-93. 2006..Stethoscope orientation preference is not a chance phenomenon and may be an expression of cerebral dominance... - Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National DatabaseEmmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
BJU Int 108:378-85. 2011.... - Future directions in castrate-resistant prostate cancer therapyEmmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Clin Genitourin Cancer 8:37-46. 2010..The future of CRPC therapy appears brighter than ever before... - Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancerE S Antonarakis
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Prostate Cancer Prostatic Dis 14:206-18. 2011.... - Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerE S Antonarakis
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Prostate Cancer Prostatic Dis 14:192-205. 2011.... - The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-upEmmanuel S Antonarakis
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Brady Urological Institute, Johns Hopkins University, Baltimore, MD 21231, USA
BJU Int 109:32-9. 2012..To describe metastasis-free survival (MFS) in men with prostate-specific antigen (PSA) recurrence following radical prostatectomy, and to define clinical prognostic factors modifying metastatic risk... - Novel targeted therapeutics for metastatic castration-resistant prostate cancerEmmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, United States
Cancer Lett 291:1-13. 2010.... - Not what it seemsEmmanuel S Antonarakis
Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
Am J Med 120:408-11. 2007 - Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancerDaniel J Zabransky
Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland
Prostate 72:487-98. 2012.... - The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivationDaniel Keizman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
Prostate 71:1608-15. 2011..We sought to determine the change of PSA doubling time (PSADT) and its association with disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer... - Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis
Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, CRB1 1M59, 1650 Orleans Street, Baltimore, MD 21231, USA
Cancer Chemother Pharmacol 69:763-71. 2012..However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK... - Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examinationDaniel Keizman
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Eur J Cancer 47:1955-61. 2011..Data suggests that they may inhibit tumourigenesis... - Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancerChanning J Paller
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231, USA
Drug Des Devel Ther 5:117-24. 2011.... - Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized studyDaniel Keizman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Clin Cancer Res 16:5269-76. 2010..To evaluate the safety and activity of 6 months of treatment with lenalidomide at 5 or 25 mg/d in nonmetastatic biochemically relapsed prostate cancer... - Current status of immunological therapies for prostate cancerEmmanuel S Antonarakis
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Curr Opin Urol 20:241-6. 2010..This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches... - An atypical complication of atypical pneumoniaEmmanuel S Antonarakis
Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
Am J Med 119:824-7. 2006 - Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?Emmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
Nat Clin Pract Oncol 6:12-3. 2009..Multi-institutional, prospective trials should provide additional information on the tolerability and activity of this compound and further define the population most likely to benefit from this endocrine approach... - Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkersEmmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
J Clin Oncol 27:4986-93. 2009..We conducted a randomized, double-blind trial to examine the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy... - Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic reviewEmmanuel S Antonarakis
Prostate Cancer Research Program, and the Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
J Clin Oncol 25:4998-5008. 2007.... - Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinomaMarc A Callender
Department of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224, USA
J Clin Rheumatol 14:121. 2008 - Update: immunological strategies for prostate cancerCharles G Drake
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 410, Baltimore, MD, 21231, USA
Curr Urol Rep 11:202-7. 2010..Enthusiasm for prostate cancer immunotherapy is founded upon its potential to mediate targeted, specific, tumor cell destruction without significant systemic toxicity; however, this has yet to be fully realized in the clinical arena... - Ruthenium-based chemotherapeutics: are they ready for prime time?Emmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
Cancer Chemother Pharmacol 66:1-9. 2010.... - Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyEmmanuel S Antonarakis
Departments of Oncology, Urology and Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Curr Opin Oncol 24:258-65. 2012..In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials... - Use of androgen deprivation therapy in prostate cancer: indications and prevalenceRoisin M Connolly
Prostate Cancer Research Program, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Asian J Androl 14:177-86. 2012..This review highlights the various androgen-directed treatment options available to men with prostate cancer, their specific indications and the evidence supporting each approach, as well as patterns of use of hormonal therapies... - Current status of immunological approaches for the treatment of prostate cancerCharles G Drake
Departments of Oncology, Urology and Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Curr Opin Urol 22:197-202. 2012.... - Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?Emmanuel S Antonarakis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
Nat Clin Pract Urol 5:480-1. 2008.... - Pemberton signEmmanuel S Antonarakis
Department of Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
Mayo Clin Proc 82:859. 2007 - A cut aboveElisabeth B Marsh
Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA
Am J Med 120:1031-3. 2007